The global market for contrast media is valued between $5 billion and $6 billion and is dominated by four players:
- GE HealthCare (USA): Manufacturer of Omnipaque (Iohexol) and Visipaque (Iodixanol).
- Bracco Imaging (Italy): Manufacturer of Isovue (Iopamidol) and Vueway (Gadopiclenol).
- Guerbet (France): Manufacturer of Xenetix (Iobitridol) and Elucirem (Gadopiclenol).
- Bayer (Germany): Manufacturer of Ultravist (Iopromide) and Gadavist (Gadobutrol).
These companies collectively control approximately 75-80% of the global market.
Blue Jet has a portfolio of over 20+ products in the contrast media segment. ABA HCl (for Iohexol) and BGB (for Gadopiclenol) are the “hero” products that generate the bulk of the volume. Below I have covered if there is any impact on both these intermediates by entry of Divis in contrast media space.
Blue Jet’s Supply Chain for ABA HCl:
- They partner with the Innovator. Handle the complex organic chemistry but leave the expensive iodine to the client.
- Sells ABA HCl (Bisamide) intermediate to GE.
- Process:
- 5-NIPA (Starting Material) → Esterification.
- Reaction with APD: Attaches the hydrophilic side chains first.
- Reduction: Converts Nitro group to Amino group.
- Result: ABA HCl (Blue Jet ships this to GE).
- Client Step: GE performs Iodination → Iohexol.
Divis Supply Chain:
- Vertical Integration Strategy. Handle the Iodine in-house to create a finished API for generics.
- Process:
- 5-NIPA → Iodination (Divi’s adds Iodine first).
- Activation: Converts to Acid Chloride (Atipadichloride).
- Coupling with APD: Reacts Atipadichloride with APD to attach side chains.
- Result: Iohexol API (Ready for formulation).
Divis installed capacities, sourced from regulatory filings (Environmental Clearance) for the now-operational Unit 3 Kakinada facility (Dedicated Contrast Media facility) using Gemini.
- Filed API Capacity: ~300 TPA (Iohexol).
- Filed Intermediate Capacity: 1,210 TPA (Atipadichloride).
- Implication: Since Atipadichloride is solely a precursor for Iohexol/Iopamidol, this backend capacity supports >1,600 TPA of final API. Divis is built to capture >10% of the global market.
Impact On Blue Jet sales of ABA HCI:
- Divis is unlikely to sell API to GE. GE has invested billions in its own supply chain (Norway/Ireland) and validated Blue Jet as a partner. Switching to Divis would require scrapping their own plants.
- Divis will likely sell this 1,600 TPA of API to generic challengers (e.g., Sandoz, Sun Pharma) who might try to capture GE’s market by cost cutting.
- However this is not going be an easy task because
- GE HealthCare doesn’t just sell contrast media; they sell the CT Scanners + Injectors + Service Contracts + Contrast Media as a bundle.
- A generic supplier (powered by Divis) can only offer the liquid. They cannot offer the machine. This “ecosystem lock-in” prevents hospitals from switching easily, even if Divis is cheaper.
- Both Divis and Blue Jet need APD (3-Amino-1,2-propanediol) to finish the molecule. Blue Jet is building a massive APD plant (Unit 3) (Going Live in H2 FY26). If Blue Jet becomes the lowest-cost producer of APD globally, even Divis might struggle to match Blue Jet’s cost structure on the non-iodinated side of the molecule.
Blue Jet’s BGB (ButylBromoGlutarate) intermediate.
- Critical intermediate for Gadopiclenol (Brand: Elucirem / Vueway).
- For a NCE like Gadopiclenol (launched 2022/2023), the supply chain is tightly controlled. The FDA and EMA regulatory filings (NDA/MAA) specify the exact manufacturing site for the Critical Intermediates.
- Blue Jet was the CDMO partner during the development phase. In the pharma industry, the partner who develops the intermediate process for an NCE becomes the exclusive supplier for the first 5-7 years of the drug’s life because validating a second supplier requires:
- New clinical bio-equivalence studies (expensive).
- Amending the regulatory filing (time-consuming).
- There is no evidence in public filings of Guerbet or Bracco validating a second source for BGB yet. (Verified using Gemini)
- Supply Chain:
- Blue Jet manufactures BGB in India and ships this primarily to Guerbet.
- Guerbet uses the BGB to manufacture the Gadopiclenol API at its plant in Marans, France (or Lanester).
- Under the 2021 agreement, Guerbet manufactures the API for both companies during the initial transition period (Till ~2029). The December 2021 agreement between Guerbet and Bracco is a Manufacturing & IP Sharing deal, not just a marketing deal.
- After the ~7-year period, Guerbet is contractually obligated to transfer the manufacturing technology to Bracco.
- After 2029: Bracco will likely set up its own manufacturing line to reduce dependence on Guerbet.
- Until ~2029, Blue Jet effectively ships BGB to one customer (Guerbet) who manufactures for the entire global market of Gadopiclenol.
- As Bracco aggressively markets Vueway to compete with Bayer’s Gadavist, every success Bracco has directly increases the order volume Guerbet places with Blue Jet.
- When Bracco starts its own manufacturing, Blue Jet will need to ensure it remains the supplier for Bracco’s new line. Given the regulatory cost of validating a new intermediate supplier, Bracco will hopefully continue buying from Blue Jet, just shipping it to a different factory.
Can Divi disrupt Blue jet’s BGB sales?
- The primary composition of matter patent for Gadopiclenol (US Patent 10,973,934 ), assigned to Bracco, expires on August 6, 2039. A related process/purification patent (US 11,590,246) expires in January 2040.
- As a NCE approved by the FDA in September 2022, it also has regulatory data exclusivity until 2027, preventing even the filing of a generic application.
- The generic lock is effective for nearly 14 more years, effectively barring Divi’s from this specific molecule.
- The only way Divi’s could touch this is if Guerbet or Bracco voluntarily hired Divi’s as a second source CDMO. However this is unlikely because:
- Divis is building capacity for Iopamidol (~300 TPA).
- Divis Iopamidol attacks Bracco’s Isovue. Bracco views Divis as a direct threat to its primary revenue stream (Isovue). Isovue (Iopamidol) is Bracco’s flagship product. It is one of the most widely used CT contrast agents in the US and Europe. It generates a massive portion of Bracco’s free cash flow. Therefore it is safe to say Bracco will not hire Divis for Gadopiclenol because Divis is actively trying to kill Bracco’s Iopamidol business.
- Divis is likely targeting off-patent agents (Gadobutrol).
- Multiple generic companies (e.g., Zydus, Hengrui, Hainan Poly) have recently received FDA approval for Generic Gadobutrol.
- Divis management has stated they are in “Phase 3/Validation” for Gadolinium compounds. Since they are a generic API powerhouse, they are almost certainly manufacturing the API for one of these new generic entrants who want to challenge Bayer’s Gadavist.
- If Divis attacks Bayer’s Gadavist with cheap generics, it damages Bayer. It does not hurt Blue Jet’s clients (Guerbet/Bracco), who are trying to migrate doctors away from Gadobutrol toward the superior Gadopiclenol.
Disclaimer: Invested & Biased. Even I was not aware of the impact before and was intrigued by the question. So had to spend my Friday night researching it.